Indeed, anti-PD-L1 treatment has been associated with less severe adverse events [13], suggesting that the differences between anti-PD1 and anti-PD-L1 agents could be clinically exploited for better tailoring of treatments to the tumor characteristics of an individual patient. The gene discussed is CD274; the disease is neoplasm.